MX2021003668A - Ketamine composition for use in a method of treatment of depression by pulmonary administration. - Google Patents

Ketamine composition for use in a method of treatment of depression by pulmonary administration.

Info

Publication number
MX2021003668A
MX2021003668A MX2021003668A MX2021003668A MX2021003668A MX 2021003668 A MX2021003668 A MX 2021003668A MX 2021003668 A MX2021003668 A MX 2021003668A MX 2021003668 A MX2021003668 A MX 2021003668A MX 2021003668 A MX2021003668 A MX 2021003668A
Authority
MX
Mexico
Prior art keywords
treatment
depression
sequences
administration
days
Prior art date
Application number
MX2021003668A
Other languages
Spanish (es)
Inventor
Sylwia Janowska
Maciej Wieczorek
Original Assignee
Celon Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Sa filed Critical Celon Pharma Sa
Publication of MX2021003668A publication Critical patent/MX2021003668A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

An inhalable pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression by administration via pulmonary route, treatment comprising cycle of multiple sequences of administration by inhalation, said cycle lasting from 10 days to 30 days, wherein each of multiple sequences of administration is performed in a one single day, with 2 to 4 days intervals between sequences, and each of said sequences consists of multiple single dose inhalations separated by a break period lasting at least 5 minutes. The composition is especially useful for the treatment of treatment-resistant depression.
MX2021003668A 2018-09-28 2019-09-24 Ketamine composition for use in a method of treatment of depression by pulmonary administration. MX2021003668A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18461615.9A EP3628313A1 (en) 2018-09-28 2018-09-28 Ketamine composition for use in a method of treatment of depression by pulmonary administration
PCT/EP2019/075735 WO2020064748A1 (en) 2018-09-28 2019-09-24 Ketamine composition for use in a method of treatment of depression by pulmonary administration

Publications (1)

Publication Number Publication Date
MX2021003668A true MX2021003668A (en) 2021-08-19

Family

ID=63713806

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003668A MX2021003668A (en) 2018-09-28 2019-09-24 Ketamine composition for use in a method of treatment of depression by pulmonary administration.

Country Status (11)

Country Link
US (1) US11925607B2 (en)
EP (2) EP3628313A1 (en)
JP (1) JP7444864B2 (en)
KR (1) KR20210068465A (en)
CN (1) CN113038941A (en)
AU (1) AU2019349624A1 (en)
BR (1) BR112021005687A2 (en)
CA (1) CA3114325A1 (en)
EA (1) EA202190724A1 (en)
MX (1) MX2021003668A (en)
WO (1) WO2020064748A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3505157T (en) * 2017-12-29 2022-02-18 Celon Pharma Sa Dry powder ketamine composition for pulmonary administration in treatment-resistant depression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
JP2009530385A (en) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン Intranasal ketamine for the treatment of depression
DE102007009888A1 (en) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
MX2014010939A (en) 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression.
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
ES2745024T3 (en) 2013-03-15 2020-02-27 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
PT3505157T (en) 2017-12-29 2022-02-18 Celon Pharma Sa Dry powder ketamine composition for pulmonary administration in treatment-resistant depression

Also Published As

Publication number Publication date
WO2020064748A1 (en) 2020-04-02
EA202190724A1 (en) 2021-08-18
EP3856159A1 (en) 2021-08-04
JP7444864B2 (en) 2024-03-06
BR112021005687A2 (en) 2021-06-22
JP2022502429A (en) 2022-01-11
EP3628313A1 (en) 2020-04-01
KR20210068465A (en) 2021-06-09
CN113038941A (en) 2021-06-25
AU2019349624A1 (en) 2021-04-29
US11925607B2 (en) 2024-03-12
US20210353560A1 (en) 2021-11-18
CA3114325A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
ZA202103404B (en) Composition and method for treating the lungs
PH12020551425A1 (en) Rimegepant for cgrp related disorders
EA033113B1 (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
PH12020550237A1 (en) Methods for the administration of certain vmat2 inhibitors
NZ726256A (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
MX2022003072A (en) Use of pridopidine for treating functional decline.
MX2014002171A (en) Combination treatments for hepatitis c.
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
EA201590933A1 (en) NEW ORAL BIO-ACCESSIBLE CONNECTIONS, MODULATING RESPIRATION CONTROL, AND METHODS OF THEIR USE
WO2012040228A3 (en) Aerosol composition for administering drugs
MX2022015629A (en) Use of vibegron to treat overactive bladder.
MX2022000430A (en) Administration of sting agonist and checkpoint inhibitors.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2021002322A (en) Novel methods.
MX2020007971A (en) Compositions and methods for treating pulmonary edema or lung inflammation.
JP2016539122A5 (en)
JP2016505050A5 (en)
MX2021003668A (en) Ketamine composition for use in a method of treatment of depression by pulmonary administration.
EA201591415A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING MULTICOMPONENT CRYSTALLINE PARTICLES, SUITABLE FOR USE IN INHALATION THERAPY
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2017002476A (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition.
JP2019529569A5 (en)
MX2021014523A (en) Methods of treating cholangiocarcinoma.
IN2014DN09240A (en)